¬³¬á¬â¬Ñ¬Ó¬Ü¬Ñ ¬à¬ä ¬á¬â¬à¬Ü¬ä¬à¬Ý¬à¬Ô¬Ñ ¬Ó ¬®¬à¬ã¬Ü¬Ó¬Ö - ¬£¬Ú¬ä¬Ò¬Ú¬à¬Þ¬Ö¬Õ+ | ||||||||||
MosmdsEvato | 2022-12-27 | 128 | ||||||||
¬³¬á¬â¬Ñ¬Ó¬Ü¬Ú ¬Õ¬Ý¬ñ ¬å¬ã¬ä¬â¬à¬Û¬ã¬ä¬Ó¬Ñ ¬ß¬Ñ ¬â¬Ñ¬Ò¬à¬ä¬å ¬Þ¬Ö¬Õ¬Ú¬è¬Ú¬ß¬ã¬Ü¬Ú¬Ö ¬Ó ¬®¬à¬ã¬Ü¬Ó¬Ö | ¬£¬Ú¬ä¬Ò¬Ú¬à¬Þ¬Ö¬Õ+ Tegs: ¬³¬á¬â¬Ñ¬Ó¬Ü¬Ú ¬Õ¬Ý¬ñ ¬Ó¬Ù¬â¬à¬ã¬Ý¬í¬ç ¬Ó ¬®¬à¬ã¬Ü¬Ó¬Ö ¬Þ¬Ö¬Õ¬Ú¬è¬Ú¬ß¬ã¬Ü¬Ú¬Ö | ¬£¬Ú¬ä¬Ò¬Ú¬à¬Þ¬Ö¬Õ+ https://mosmedspravki.ru/spravki-dlya-vzroslyh/ ¬³¬á¬â¬Ñ¬Ó¬Ü¬Ñ ¬à¬ä ¬Ü¬Ñ¬â¬Õ¬Ú¬à¬Ý¬à¬Ô¬Ñ ¬ß¬Ñ ¬â¬Ñ¬Ò¬à¬ä¬å ¬Ó ¬®¬à¬ã¬Ü¬Ó¬Ö - ¬£¬Ú¬ä¬Ò¬Ú¬à¬Þ¬Ö¬Õ+ ¬³¬á¬â¬Ñ¬Ó¬Ü¬Ñ ¬à¬ä ¬ß¬Ö¬Ó¬â¬à¬Ý¬à¬Ô¬Ñ ¬Ó ¬®¬à¬ã¬Ü¬Ó¬Ö - ¬£¬Ú¬ä¬Ò¬Ú¬à¬Þ¬Ö¬Õ+ ¬³¬á¬â¬Ñ¬Ó¬Ü¬å ¬à¬ä ¬à¬ß¬Ü¬à¬Ý¬à¬Ô¬Ñ ¬Ü¬å¬á¬Ú¬ä¬î ¬Ó ¬®¬à¬ã¬Ü¬Ó¬Ö - ¬£¬Ú¬ä¬Ò¬Ú¬à¬Þ¬Ö¬Õ+ |
18586 | endostatin murine, recombinant ¬Ü¬å¬á¬Ú¬ä¬î ¬à¬ß¬Ý¬Ñ... | LavillEvat | 2024-04-03 | 3 | |
18585 | anti-histone deacetylase 1 (hdac1) anti& ¬Ü¬å¬á¬Ú¬ä... | LavillEvat | 2024-03-31 | 4 | |
18584 | First revalidation, dilatation ptosis accountability... | axojaqeera | 2024-01-05 | 31 | |
18583 | L, documentation rotational, expressed accountabilit... | axojaqeera | 2024-01-05 | 31 | |
18582 | ¬Ü¬à¬Ý¬à¬ß¬Ü¬Ñ ¬Õ¬Ý¬ñ ¬Ó¬ï¬Ø¬ç caprisil c18 5 ¬Þ¬Ü¬Þ... | LavillEvat | 2023-10-28 | 65 | |
18581 | pyrex(r) vista(tm) volumetric pipette, & ¬Ü¬å¬á¬Ú¬ä... | LavillEvat | 2023-10-18 | 59 | |
18580 | 5-chloro-2-[(4-fluorobenzyl)oxy]benzoyl chloride †... | LavillEvat | 2023-10-13 | 65 | |
18579 | human gabrr1 gene orf cdna clone expression plasmid ... | LavillEvat | 2023-10-07 | 69 | |
18578 | Consider rehabilitating total symptom memory, append... | eshuhia | 2023-09-22 | 75 | |
18577 | Consider case-control crescent higher, health-relate... | eshuhia | 2023-09-22 | 69 | |
1 2 3 4 5 6 7 8 9 10 |